Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Up 41.4% in February

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 108,439 shares, a growth of 41.4% from the January 29th total of 76,665 shares. Based on an average daily volume of 74,262 shares, the days-to-cover ratio is currently 1.5 days. Approximately 3.1% of the company’s stock are sold short. Approximately 3.1% of the company’s stock are sold short. Based on an average daily volume of 74,262 shares, the days-to-cover ratio is currently 1.5 days.

Analysts Set New Price Targets

QNTM has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday, December 29th. Wall Street Zen downgraded shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma presently has an average rating of “Sell”.

Quantum Biopharma Stock Performance

Shares of QNTM stock traded down $0.03 during mid-day trading on Friday, hitting $3.55. 31,228 shares of the stock traded hands, compared to its average volume of 54,635. Quantum Biopharma has a twelve month low of $3.51 and a twelve month high of $38.25. The company’s 50-day simple moving average is $5.75 and its 200-day simple moving average is $10.81. The firm has a market cap of $13.55 million, a price-to-earnings ratio of -0.33 and a beta of 0.30.

Hedge Funds Weigh In On Quantum Biopharma

Several large investors have recently bought and sold shares of QNTM. Steward Partners Investment Advisory LLC bought a new position in shares of Quantum Biopharma during the second quarter valued at $63,000. Virtu Financial LLC acquired a new stake in shares of Quantum Biopharma during the fourth quarter worth about $76,000. Finally, Jane Street Group LLC acquired a new stake in shares of Quantum Biopharma during the fourth quarter worth $80,000. 1.24% of the stock is currently owned by institutional investors and hedge funds.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.